Johnson & Johnson’s Prostate Drug Shows 75% Tumor Response
Johnson & Johnson’s JNJ-6143 showed early activity in advanced prostate cancer, with a 50-mg daily dose selected for further study, including Phase 2.

Johnson & Johnson reported a 75% confirmed complete or partial tumor response rate among imaging-evaluable patients in a Phase 1 study of JNJ-6143 for previously treated advanced prostate cancer.
Johnson & Johnson (NYSE: JNJ) reported a 75% confirmed tumor response rate among patients whose cancer could be measured by imaging in an early study of JNJ-6143, its investigational once-daily prostate cancer drug. The result supports further development, but comes from a Phase 1 trial with a median follow-up of 5.6 months for patients receiving the selected 50-mg dose.
The study enrolled patients whose advanced prostate cancer had progressed after treatment. They had received a median of four prior therapies, including chemotherapy and radioligand therapy targeting prostate-specific membrane antigen, or PSMA. That treatment history makes the findings relevant to patients whose remaining options have narrowed.
Johnson & Johnson detailed the findings in an announcement carried by PR Newswire Biotech.
Imaging responses and PSA declines measure different outcomes
The 75% figure represents confirmed complete or partial responses among patients with tumors measurable on imaging. It should not be read as a response rate for every patient in the study, or as evidence that the drug extends survival.
A separate measure of activity came from blood tests. Among 38 patients receiving 50 mg once daily, 77% had a confirmed decline of at least 50% in prostate-specific antigen, or PSA, a protein used to help monitor prostate cancer. That included 48% whose PSA levels fell by at least 90%.
These PSA results support the evidence of anti-tumor activity, but a decline in a blood marker is not the same outcome as tumor shrinkage on a scan. Johnson & Johnson also reported PSA reductions in patients with high-risk molecular features associated with difficult-to-treat disease.
These PSA results support the evidence of anti-tumor activity, but a decline in a blood marker is not the same outcome as tumor shrinkage on a scan.
At the analysis cutoff, 71% of patients receiving 50 mg remained on treatment. Continued treatment and the short median follow-up leave the durability of the early responses as an important question for subsequent study.
Safety findings accompany selection of the 50-mg dose
The most common treatment-related adverse events were elevated cholesterol levels in 18% of patients, nausea in 16%, and elevated triglyceride levels in 16%. Four patients, or 11%, interrupted dosing because of adverse events. One patient, or 3%, reduced the dose, and one patient, or 3%, discontinued treatment.
Dose escalation tested once-daily amounts ranging from 12.5 mg to 150 mg. The expansion portion randomized patients to 25 mg or 50 mg daily. Based on clinical activity, safety and pharmacokinetic data—how the drug behaves in the body—the company identified 50 mg as the preliminary optimal dose. It will advance into further development, including a Phase 2 study.
A different use of the androgen receptor
JNJ-6143 is the first molecule from Johnson & Johnson’s RIPTAC platform to enter clinical studies. It is designed to bring together BRD4, a protein essential to cell survival, and the androgen receptor, which is highly expressed in prostate cancer cells. This targeted pairing is intended to disrupt cancer-cell function and trigger cell death.
The approach seeks to exploit the androgen receptor in cancers that have progressed despite treatments targeting its pathway. The early results provide a reason to test that mechanism further; the next development stage will need to establish whether the activity and tolerability observed so far persist with longer treatment.
Key facts
- Company: Johnson & Johnson (NYSE: JNJ)
- Imaging response: 75% confirmed complete or partial response among patients with measurable tumors
- Selected-dose cohort: 38 patients received 50 mg once daily; median follow-up was 5.6 months
- Next development step: 50-mg once-daily dose to advance, including into Phase 2
Sources
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule — PR Newswire Biotech
Photo: Edward Jenner · Pexels Licence — source


